Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma
Crossref DOI link: https://doi.org/10.1007/s11060-016-2287-6
Published Online: 2016-11-14
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Phuphanich, Surasak
Raizer, Jeffrey
Chamberlain, Marc
Canelos, Paola
Narwal, Rajesh
Hong, Shengyan
Miday, Robert
Nade, Minal
Laubscher, Kevin
Funding for this research was provided by:
MedImmune LLC
License valid from 2016-11-14